Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Abciximab

Catalog #:   DHC33301 Specific References (98) DATASHEET
Host species: Chimeric
Isotype: Fab-G1-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHC33301

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Chimeric

Isotype

Fab-G1-kappa

Clonality

Monoclonal

Target

CD41, ITGAB, GPIIb, ITGA2B, Platelet membrane glycoprotein IIb, GP2B, Integrin alpha-IIb, GPalpha IIb, GPIIIa, Integrin beta-3, CD61, ITGB3, Platelet membrane glycoprotein IIIa, GP3A

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P08514 & P05106

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

c7E3, CAS: 143653-53-6

Clone ID

Abciximab

Data Image
  • SDS-PAGE
    SDS PAGE for Abciximab
References

[Abciximab], PMID: 17465067

How abciximab might be clinically useful, PMID: 27519521

Cryo-Electron Microscopy Structure of the αIIbβ3-Abciximab Complex, PMID: 31969014

Abciximab as an adjunctive therapy for patients undergoing percutaneous coronary interventions, PMID: 21204736

ABCIXIMAB: a new antiaggregant used in angioplasty, PMID: 8833561

Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation, PMID: 10724797

Abciximab/Heparin During Acute Heparin-Induced Thrombocytopenia: A Word of Caution, PMID: 29305853

Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease, PMID: 7528131

A review of intracoronary abciximab in percutaneous coronary interventions--where are we now and where do we go from here?, PMID: 23957238

Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions, PMID: 21942506

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention, PMID: 20234778

Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting, PMID: 30845955

Current status of cardiac surgery in the abciximab-treated patient, PMID: 10966006

Intracoronary tenecteplase versus abciximab as adjunctive treatment during primary percutaneous coronary intervention in patients with anterior myocardial infarction, PMID: 30418157

Effect of Intravenous Abciximab on Coronary Flow Improvement After Re-vascularization in Primary Coronary Intervention and Short Term Impact, PMID: 33041442

Optimizing the use of abciximab and intracoronary stents in patients with acute ST elevation myocardial infarction, PMID: 14727961

Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention, PMID: 30460974

Intracoronary Abciximab in Diabetic STEMI Patients: Questionable Benefit, Proven Harm, PMID: 27515334

Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach?, PMID: 16891291

Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients, PMID: 27366874

Clinical experience in coronary bypass surgery for abciximab-treated patients, PMID: 10966008

Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications, PMID: 11033455

Reply, PMID: 29371038

On the use of abciximab in percutaneous coronary intervention, PMID: 21827726

Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment, PMID: 30154253

Cangrelor or Abciximab as First Choice in Cardiogenic Shock, PMID: 29217012

Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis, PMID: 31542257

In situ administration of abciximab for thrombus resolution during intracranial bypass surgery: case report, PMID: 29350605

Understanding the complexity of abciximab-related thrombocytopenia, PMID: 20135055

Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial, PMID: 22447888

Use of intravenous abciximab as adjunctive therapy for carotid angioplasty and stent placement, PMID: 12745860

Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock, PMID: 29217013

Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials, PMID: 15827315

Bilateral subconjunctival hemorrhage secondary to abciximab use: case report, PMID: 29267537

Abciximab and excessive bleeding in patients undergoing emergency cardiac operations, PMID: 9485247

Thromboaspiration and IIb/IIIa therapy in STEMI: abciximab redux?, PMID: 24078419

[Abciximab in the treatment of acute coronary syndromes by angioplasty and stents], PMID: 9806003

Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?, PMID: 11773572

Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis, PMID: 12112910

Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis, PMID: 20516508

Abciximab extends treatment window for stroke, PMID: 12849109

Intracoronary abciximab in STEMI using local drug delivery catheter - single center experience, PMID: 23809377

Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up, PMID: 17251257

Periprocedural abciximab administration in ST elevation myocardial infarction patients. Effect on severe microvascular obstruction beyond the restoration of epicardial coronary flow by primary angioplasty, PMID: 17971662

Readministration of abciximab in percutaneous coronary intervention, PMID: 10745525

Concentration-dependent effect of abciximab on platelets and neutrophils in a model of cardiopulmonary bypass, PMID: 17312858

High-bolus dose tirofiban compared with abciximab in primary percutaneous coronary intervention: a propensity score-matched outcome study, PMID: 24831494

Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction, PMID: 12587942

Abciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factor, PMID: 16015412

Stenting and abciximab in primary angioplasty: a review of current status, PMID: 16320920

Simultaneous Determination of Atezolizumab and Bevacizumab by LC-MS/MS in Rat Plasma and Its Application to a Pharmacokinetic Study., PMID:40525526

Coronary artery ectasia presenting as acute coronary syndrome and misinterpreted as coronary artery perforation: Case report., PMID:40324275

Red blood cell aggregation within a blood clot causes platelet-independent clot shrinkage., PMID:40238947

Assessment of the prognostic performance of TIMI, PAMI, CADILLAC and GRACE scores for short-term major adverse cardiovascular events in patients undergoing emergent percutaneous revascularisation: a prospective observational study., PMID:40074268

Catheter-Directed Thrombolysis in the Management of Thrombotic Peripheral Artery Occlusions-Acute and Mid-Term Clinical Outcomes., PMID:39407791

Current and Future Roles of Glycoprotein IIb-IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction., PMID:39335537

Role of Intracoronary Adrenaline in the Treatment of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention., PMID:38883139

The Relationship of Coronary Thrombus Burden and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Score in Patients With ST-Segment Elevation Myocardial Infarction., PMID:38644774

Qualitative classification of thrombus images as a way to improve quantitative analysis of thrombus formation in flow chamber assays., PMID:38466712

A novel technique to quantify the kinetics of blood clot contraction based on the expulsion of fluorescently labeled albumin into serum., PMID:38401713

Derivation and validation of the incomplete ST-segment resolution score and its usefulness for treatment with glycoprotein IIb-IIIa inhibitors., PMID:38149704

A Fatal Case of Acute Thrombotic Occlusion in More Than 3 Epicardial Coronary Arteries Associated with the Yasmin Oral Contraceptive., PMID:38146410

Adverse Drug Effect Profiles of Gp2b/3a Inhibitors: A Comparative Review of the Last Two Decades., PMID:38143693

Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s)., PMID:38063187

Self-Reporting Theranostic: Nano Tool for Arterial Thrombosis., PMID:37760122

Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion., PMID:37682072

Efficacy, Safety, and Role of Antiplatelet Drugs in the Management of Acute Coronary Syndrome: A Comprehensive Review of Literature., PMID:37077602

Glycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis., PMID:36961079

[Comparison of the predictive value of the modified CADILLAC, GRACE and TIMI risk scores for the risk of short-term death in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention]., PMID:36916344

Association between the number of Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome., PMID:36682715

An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives., PMID:36637623

Comparison of Different Risk Scores for Prediction of In-Hospital Mortality in STEMI Patients Treated with PPCI., PMID:36619804

Targeting integrin pathways: mechanisms and advances in therapy., PMID:36588107

GPIIb/IIIa Receptor Targeted Rutin Loaded Liposomes for Site-Specific Antithrombotic Effect., PMID:36413707

Anti-Platelet Peptides Targeting αIIbβ3 Outside-In Signaling Pathway., PMID:36380406

It's the water! The open and shut case of drug-induced integrin activation., PMID:36113425

Efficient delivery of abciximab using mesoporous silica nanoparticles: In-vitro assessment for targeted and improved antithrombotic activity., PMID:35917688

Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials., PMID:35685429

Construction of miRNA-regulated drug-pathway network to screen drug repurposing candidates for multiple sclerosis., PMID:35356949

Antiplatelet agents for chronic kidney disease., PMID:35224730

Alveolar Hemorrhage during Abciximab Infusion., PMID:35082871

A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES., PMID:35071113

A New Score for Determining Thrombus Burden in STEMI Patients: The MAPH Score., PMID:35018837

Monoclonal antibodies as a trick or treat for COVID-19? The example of abciximab., PMID:34984684

Ruptured Proximal Anterior Cerebral Artery Aneurysm Treated with Flow Diverter., PMID:34859825

Thrombocytopathy vs Platelet hyper-reactivity in COVID-19: diverse pathologies, disease outcomes and therapeutic implications., PMID:34847829

Mechanical clot dissolution technique for surgical clip-related occlusions: An emergent triple-step approach., PMID:34667905

Variation in Pharmacologic Management of Patients with Kawasaki Disease with Coronary Artery Aneurysms., PMID:34474088

Acute phase segmental radial strain correlates with recovery and late gadolinium extent in ST-elevation myocardial infarction (STEMI): analysis of the abciximab intracoronary versus intravenously drug application in STEMI substudy., PMID:34341734

Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction., PMID:34031019

Impact of CADILLAC and GRACE risk scores on short- and long-term clinical outcomes in patients with acute myocardial infarction., PMID:33947628

Intravenous abciximab as a rescue therapy for immediate reocclusion after successful mechanical thrombectomy in acute ischemic stroke patients., PMID:33840346

Electron microscopy shows that binding of monoclonal antibody PT25-2 primes integrin αIIbβ3 for ligand binding., PMID:33760023

Delayed thrombocytopenia following administration of abciximab: Pharmacovigilance survey and literature review., PMID:33726948

Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead., PMID:33677829

Lysis of arterial thrombi by perfusion of N,N'-Diacetyl-L-cystine (DiNAC)., PMID:33630932

Be aware of misdiagnosis tied to COVID-19 focusing: a case report of abciximab-induced alveolar haemorrhage thought to be SARS-CoV-2 in a patient with ST-segment elevation myocardial infarction., PMID:33623858

Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention., PMID:33560898

Datasheet

Document Download

Research Grade Abciximab.pdf

 

$ 484
Product specifications
100 μg 484 1 mg 1932

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Abciximab [DHC33301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only